Intermediate weight-adjusted dose nadroparin:

• < 50 kg: 3800 IU subcutaneously once-daily;
• 50 to < 70 kg: 5700 IU subcutaneously once-daily;
• 70 to < 100 kg: 7600 IU subcutaneously once-daily;
• 100 kg or above: 9500 IU subcutaneously once-daily.

Fixed low dose enoxaparin:

• < 100 kg: 40 mg subcutaneously once-daily
• 100 kg and above: 60 mg subcutaneously once-daily

Intermediate weight-adjusted dose enoxaparin:

• < 50 kg: 60 mg subcutaneously once-daily, or;
• 50 kg to < 70 kg: 80 mg subcutaneously once-daily, or;
• 70 kg to < 100 kg: 100 mg subcutaneously once-daily, or;
• 100 kg or above: 120 mg subcutaneously once-daily.

Fixed low dose dalteparin:

• < 100 kg: 5000 IU subcutaneously once-daily
• 100 kg and above: 7500 IU subcutaneously once-daily

Intermediate weight-adjusted dose dalteparin:

• < 50 kg: 7500 IU subcutaneously once-daily, or;
• 50 kg to < 70 kg: 10000 IU subcutaneously once-daily, or;
• 70 kg to < 100 kg: 12500 IU subcutaneously once-daily, or;
• 100 kg or above: 15000 IU subcutaneously once-daily.

Fixed low dose tinzaparin:

• < 100 kg: 3500 IU subcutaneously once-daily
• 100 kg and above: 4500 IU subcutaneously once-daily

Intermediate weight-adjusted dose tinzaparin:

• < 50 kg: 4500 IU subcutaneously once-daily, or;
• 50 kg to < 70 kg: 7000 IU subcutaneously once-daily, or;
• 70 kg to < 100 kg: 10000 IU subcutaneously once-daily, or;
• 100 kg or above: 12000 IU subcutaneously once-daily.

All events of symptomatic pulmonary embolism in subjects will be recorded from the the date of randomization up to 3 months postpartum.

Definition of symptomatic pulmonary embolism (PE):

Suspected PE with one of the following findings:

• A (new) intraluminal filling defect in subsegmental or more proximal branches on spiral CT scan
• A (new) intraluminal filling defect or an extension of an existing defect or a new sudden cut-off of vessels more than 2.5 mm in diameter on the pulmonary angiogram
• A (new) perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)

See 'Major bleeding' for the definition.

Clinically relevant non-major bleeding is defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact (visit or telephone call) with a physician, (temporary) cessation of study treatment, or associated with discomfort such as pain, or impairment of activities of daily life.

• Hematuria if it is macroscopic, and either spontaneous or lasts for more than 24 hours after instrumentation (e.g. catheter placement or surgery) of the urogenital tract, or
• Macroscopic gastro-intestinal haemorrhage: at least one episode of melena/hematemesis, if clinically apparent, or
• Rectal blood loss, if more than a few spots, or
• Hemoptysis, if more than a few speckles in the sputum, or
• Intramuscular hematoma, or
• Subcutaneous hematoma if the size is larger than 25 cm2, or larger than 100 cm2 if provoked, or
• Multiple source bleeding

Postpartum haemorrhage is defined as blood loss of more than 500 mL within 24 hours of delivery (WHO-criteria). Severe postpartum haemorrhage is defined as blood loss of more than 1000 mL within 24 hours of delivery.

Postpartum haemorrhage is defined as blood loss of more than 500 mL within 24 hours of delivery (WHO-criteria). Severe postpartum haemorrhage is defined as blood loss of more than 1000 mL within 24 hours of delivery.

Minor bleeding is defined as all other overt bleeding episodes not meeting the criteria for major or clinically relevant bleeding or postpartum haemorrhage.

e.g. itching, swelling, pain

Heparin-induced thrombocytopenia is defined according to the criteria of the ACCP guidelines.